Achieve Life Sciences Elects Board at Annual Meeting

Achieve Life Sciences ( (ACHV) ) has issued an announcement.

On June 4, 2025, Achieve Life Sciences held its Annual Meeting of Stockholders, where seven directors were elected to the board. The meeting also ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. However, a proposed amendment to increase shares in the 2023 Non-Employee Director Equity Incentive Plan was not approved.

The most recent analyst rating on (ACHV) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page.

Spark’s Take on ACHV Stock

According to Spark, TipRanks’ AI Analyst, ACHV is a Underperform.

Achieve Life Sciences is navigating typical early-stage biotech challenges, including zero revenue and significant financial losses. While there are promising developments such as the upcoming NDA submission and strong clinical trial progress, these are offset by high operating expenses and dependency on future financing and regulatory approvals. Technical indicators reflect a downward trend, and the valuation remains unattractive with a negative P/E ratio.

To see Spark’s full report on ACHV stock, click here.

More about Achieve Life Sciences

Achieve Life Sciences, Inc. operates in the life sciences industry, focusing on the development and commercialization of products to address addiction and other unmet medical needs.

Average Trading Volume: 233,046

Technical Sentiment Signal: Sell

Current Market Cap: $132.8M

For an in-depth examination of ACHV stock, go to TipRanks’ Stock Analysis page.